Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes
10.3760/cma.j.issn.1000-6699.2012.06.002
- VernacularTitle:自体外周造血干细胞移植——治疗1型糖尿病的新曙光
- Author:
Lirong LI
;
Dalong ZHU
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 1;
Autologous hematopoietic stem cell transplantation;
Immune function;
C-peptide
- From:
Chinese Journal of Endocrinology and Metabolism
2012;28(6):448-451
- CountryChina
- Language:Chinese
-
Abstract:
Type 1 diabetes is pathologically characterized by autoimmune insulitis-related islet β-cell destruction.Although intensive insulin therapy for patients with type 1 diabetes can correct hyperglycemia,this therapy does not effectively prevent diabetes-related cardiovascular complications.Hence,preservation of natural β-cell function is critical for the prevention of diabetes-related complications.Receut studies have shown that autologous hematopoietic stem cell transplantation ( A HSCT) is a new promising approach for the treatment of type 1 diabetes by reeonstitution of immunotolerance and preservation of islet β-cell function.Here we introduce the key results of a clinical trial ( NCT 01341899,ClinicalTrials.gov) performed in Chinese type 1 diabetes patients ( most of them with diabetic ketoacidosis at onset ) and discuss the potential mechanisms underlying the action of HSCT and its prospects in the clinical management of type 1 diabetes.
